By Sam Schulz ( October 26, 2007, 12:00 AM EDT) -- Sanofi-Aventis has bulwarked its defenses against Novo Nordisk A/S and stepped up its demands for relief in their insulin pen spat with a dozen counterclaims, citing a licensing deal it said prevented Novo from suing and pointing to the company's history of crying wolf with patent suits it eventually withdraws....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.